☆ 4.6 Letter

Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

卷 9, 期 10, 页码 2103-2105

出版社

WILEY-BLACKWELL

DOI: 10.1111/j.1538-7836.2011.04453.x

关键词

-

类别

Hematology Peripheral Vascular Disease

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

Guiomar Mendieta, Shamir Mehta, Usman Baber, Dominick J. Angiolillo, Carlo Briguori, David Cohen, Timothy Collier, George Dangas, Dariusz Dudek, Javier Escaned, Robert Gil, Birgit Vogel, Davide Cao, Alessandro Spirito, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Vijay Kunadian, David J. Moliterno, E. Magnus Ohman, Gennaro Sardella, Samantha Sartori, Samin Sharma, Richard Shlofmitz, P. Gabriel Steg, Ya-Ling Han, Stuart Pocock, C. Michael Gibson, Roxana Mehran

Summary: In high-risk patients, ticagrelor monotherapy reduces bleeding events without increasing the risk of ischemic events compared to dual antiplatelet therapy. The benefit of ticagrelor monotherapy is consistent across different bleeding and ischemic risk levels.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

添加到收藏夹

Article Hematology

P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions

Christina C. Rolling, Marcin A. Sowa, Tricia T. T. Wang, MacIntosh Cornwell, Khrystyna Myndzar, Tamar Schwartz, Hanane El Bannoudi, Jill Buyon, Tessa J. Barrett, Jeffrey S. Berger

Summary: Monocyte-platelet aggregates (MPAs) play a role in the intersection of thrombosis and inflammation, and targeting this axis could suppress thromboinflammation. The effect of platelets on monocyte activation and the impact of antiplatelet therapy (APT) on MPA and platelet-induced monocyte activation were analyzed.

THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients The MACT Pilot Study

Seung-Yul Lee, Young-Hoon Jeong, Kyeong Ho Yun, Jae Young Cho, Diana A. Gorog, Dominick J. Angiolillo, Jin Won Kim, Yangsoo Jang

Summary: This study investigated the feasibility of combining low-dose colchicine with ticagrelor or prasugrel P2Y12 inhibitor monotherapy immediately after PCI in ACS patients. The results showed that this treatment approach is associated with reduced platelet reactivity, decreased inflammation levels, and fewer stent thrombosis events.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

添加到收藏夹

Article Hematology

Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation

Freek W. A. Verheugt, Kurt Huber, Peter Clemmensen, Jean-Philippe Collet, Thomas Cuisset, Felicita Andreotti

Summary: Antiplatelet therapy is crucial for preventing secondary ischemic heart disease. After PCI, temporary DAPT, which consists of aspirin and an oral P2Y12 receptor blocker, is recommended. However, long-term DAPT increases the risk of bleeding compared to aspirin monotherapy. To reduce bleeding, shorter DAPT duration or switching to P2Y12 inhibitor monotherapy have been suggested. This survey reviews the evidence and provides clinical guidance on the use of P2Y12 inhibitor monotherapy after DAPT cessation following PCI.

THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention - Understanding the debate on Prasugrel or Ticagrelor

Andreas Schaefer, Johann Bauersachs

Summary: A debate about the preference of prasugrel over ticagrelor has been sparked by the publication of the ISAR-REACT 5 trial, which compared both substances in patients with ACS. The trial showed superior efficacy of prasugrel over ticagrelor in general, and of deferred administration of prasugrel over pre-treatment with ticagrelor in NSTE-ACS patients undergoing percutaneous coronary interventions. The European guidelines for NSTE-ACS have adopted these preferences.

PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Hematology

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study

Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K. Jennings, Dominick J. Angiolillo

Summary: This study aimed to assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and compare the pharmacodynamic (PD) profiles of these treatments. The results showed that switching from various DAPT regimens to DPI was feasible in patients with chronic coronary syndrome (CCS), with enhanced P2Y(12) inhibition with DAPT and reduced thrombin generation with DPI. There were no differences in platelet-mediated global thrombogenicity between DPI and ticagrelor- and prasugrel-based DAPT, but differences were observed with clopidogrel-based DAPT.

THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention

Arun Kumar, Pamela L. Lutsey, Wendy L. St. Peter, Jon C. Schommer, Jeremy R. Van't Hof, Abhijeet Rajpurohit, Joel F. Farley

Summary: In acute coronary syndrome following percutaneous coronary intervention, newer P2Y12 inhibitors (ticagrelor and prasugrel) reduce cardiovascular outcomes compared to clopidogrel, but have a higher bleeding risk. This study examines the safety of each inhibitor in a real-world population.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

Dominick J. Angiolillo, Davide Cao, Samantha Sartori, Usman Baber, George Dangas, Zhongjie Zhang, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J. Cohen, Timothy Collier, Dariusz Dudek, Michael Gibson, Robert Gil, Kurt Huber, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Alfonso Ielasi, Giulio G. Stefanini, Carlo A. Pivato, Shamir Mehta, David J. Moliterno, E. Magnus Ohman, Javier Escaned, Gennaro Sardella, Samin K. Sharma, Richard Shlofmitz, Giora Weisz, Bernhard Witzenbichler, P. Gabriel Steg, Stuart Pocock, Roxana Mehran

Summary: This study found that nearly 10% of patients receiving ticagrelor therapy experienced dyspnea-related discontinuation of treatment. Asian race, smoking, prior PCI, and other factors were identified as predictors of dyspnea-related ticagrelor discontinuation. Ticagrelor monotherapy after discontinuation did not increase the risk of subsequent cardiovascular events.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

添加到收藏夹

Article Peripheral Vascular Disease

Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y12 Inhibitor Thereafter

Shqipdona Lahu, Peter Bristot, Senta Gewalt, Alexander Goedel, Daniele Giacoppo, Stefanie Schuepke, Heribert Schunkert, Adnan Kastrati, Nikolaus Sarafoff

Summary: This meta-analysis demonstrates that short-term dual antiplatelet therapy (<= 3 months), followed by single antiplatelet therapy, can reduce bleeding risk without increasing the risk of stent thrombosis.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)

添加到收藏夹

Review Cell Biology

Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand?

Kirsten Leeten, Nicolas Jacques, Patrizio Lancellotti, Cecile Oury

Summary: Infective endocarditis is a challenging disease with high mortality and morbidity rates. Antibiotic prophylaxis is recommended in high-risk patients but faces challenges of low efficacy and antibiotic resistance. Platelets play a crucial role in the disease, but there are still many unanswered questions about their antimicrobial activities in infective endocarditis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials

Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, Hwee Teoh, Kim Fox, Tabassome Simon, Shamir R. Mehta, Eli I. Lev, Robert G. Kiss, Anthony J. Dalby, Hector Bueno, Wilhelm Ridderstrale, Anders Himmelmann, Jayne Prats, Yuyin Liu, Jane J. Lee, John Amerena, Mikhail N. Kosiborod, Philippe Gabriel Steg

Summary: The THEMIS study and its subanalysis THEMIS-PCI showed that ticagrelor plus aspirin had a favorable net clinical benefit in individuals with type 2 diabetes and stable coronary artery disease, particularly among those who had previous percutaneous coronary intervention. The efficacy of ticagrelor plus aspirin on reducing major adverse cardiovascular events was generally consistent across subgroups, while the major bleeding event rate was increased by ticagrelor across all subgroups. Additionally, in THEMIS-PCI but not in the overall THEMIS population, ticagrelor generally produced a favorable net clinical benefit across different diabetes-related factors.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention

Larisa H. H. Cavallari, Nita A. A. Limdi, Amber L. L. Beitelshees, James C. C. Lee, Julio D. D. Duarte, Francesco Franchi, Sony Tuteja, Jay Giri, Philip E. E. Empey, Rolf P. P. Kreutz, Todd C. C. Skaar, John M. M. Allen, James C. C. Coons, Yan Gong, Caitrin W. W. McDonough, James M. M. Stevenson, Cameron D. D. Thomas, Julie A. A. Johnson, George A. A. Stouffer, Dominick J. J. Angiolillo, Craig R. Lee

Summary: Black patients and White patients have similar rates of P2Y(12) inhibitor prescribing after genotype-guided antiplatelet therapy selection following percutaneous coronary intervention (PCI).

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Hematology

P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials

Yao Jin, Hui Huang, Xinyi Shu, Shuai Chen, Lin Lu, Xiang Gao, Zhijun Wu

Summary: The study found that P2Y(12) inhibitor monotherapy following short-term DAPT significantly reduced the risk of BARC type 3 or 5 bleeding compared to standard DAPT, without significant difference in reducing the composite CVD outcomes.

THROMBOSIS RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Claiborne Johnston, Hao Li, Philip M. Bath, Qiang Dong, Anding Xu, Jing Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, Liguo Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang

Summary: This study compared ticagrelor and clopidogrel for the secondary prevention of stroke in Chinese patients with minor ischemic stroke or TIA who carried CYP2C19 loss-of-function alleles. The results showed that ticagrelor was associated with a modestly lower risk of stroke at 90 days compared to clopidogrel, with no difference in severe or moderate bleeding risk between the two treatment groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology

Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor

Uta Schilling, Jasper Dingemanse, Michael Dobrow, Martine Baumann, Markus A. Riederer, Pierre-Eric Juif, Mike Ufer

Summary: The novel P2Y(12) receptor antagonist selatogrel showed reduced pharmacodynamic effects when administered with irreversible oral P2Y(12) receptor antagonists like clopidogrel and prasugrel, but had no significant interaction with reversible antagonist ticagrelor in both in vitro and clinical studies.

THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis

Nicholas S. Kirkby, Joan Raouf, Blerina Ahmetaj-Shala, Bin Liu, Sarah Mazi, Matthew L. Edin, Mark Geoffrey Chambers, Marina Korotkova, Xiaomeng Wang, Walter Wahli, Darryl C. Zeldin, Rolf Nusing, Yingbi Zhou, Per-Johan Jakobsson, Jane A. Mitchell

CARDIOVASCULAR RESEARCH (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A bioassay system of autologous human endothelial, smooth muscle cells, and leukocytes for use in drug discovery, phenotyping, and tissue engineering

Blerina Ahmetaj-Shala, Ryota Kawai, Isra Marei, Zacharoula Nikolakopoulou, Chih-Chin Shih, Bhatti Konain, Daniel M. Reed, Roisin Mongey, Nicholas S. Kirkby, Jane A. Mitchell

FASEB JOURNAL (2020)

添加到收藏夹

Article Hematology

Identification of a homozygous recessive variant in PTGS1 resulting in a congenital aspirin-like defect in platelet function

Melissa Chan, Melissa A. Hayman, Suthesh Sivapalaratnam, Marilena Crescente, Harriet E. Allan, Matthew L. Edin, Darryl C. Zeldin, Ginger L. Milne, Jonathan Stephens, Daniel Greene, Moghees Hanif, Valerie B. O'Donnell, Liang Dong, Michael G. Malkowski, Claire Lentaigne, Katherine Wedderburn, Matthew Stubbs, Kate Downes, Willem H. Ouwehand, Ernest Turro, Daniel P. Hart, Kathleen Freson, Michael A. Laffan, Timothy D. Warner

Summary: This study identified a rare PTGS1 variant associated with a bleeding phenotype and alterations in platelet reactivity and eicosanoid production in a large consanguineous family. The specific loss of platelet COX-1 activity was demonstrated for the first time in humans, providing important insights into platelet function and eicosanoid metabolism. Despite the absence of thromboxane A(2) formation by platelets, urinary thromboxane A(2) metabolites were in the normal range, suggesting the need for caution when using them as markers of in vivo platelet function.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti-platelet therapy

Paul C. Armstrong, Plinio M. Ferreira, Melissa V. Chan, Martina H. Lundberg Slingsby, Marilena Crescente, Chih-Chin Shih, Nicholas S. Kirkby, Adrian J. Hobbs, Timothy D. Warner

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation

Jane A. Mitchell, Fisnik Shala, Maria Elisa Lopes Pires, Rachel Y. Loy, Andrew Ravendren, Joshua Benson, Paula Urquhart, Anna Nicolaou, Harvey R. Herschman, Nicholas S. Kirkby

Summary: The endothelial cyclooxygenase-1 produces both protective and pathological products, ultimately leading to pathological responses such as vasoconstriction in vitro and the development of atherosclerosis and vascular inflammation in vivo. This highlights the potential of the vascular cyclooxygenase-1 pathway as a therapeutic target and emphasizes that the role of prostanoids in biology is complex and context-dependent.

SCIENCE ADVANCES (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators

Chih-Chin Shih, Melissa Chan, Nicholas S. Kirkby, Ivana Vojnovic, Jane A. Mitchell, Paul C. Armstrong, Timothy D. Warner

Summary: The study demonstrates a synergistic relationship between P2Y(12) receptor antagonists and adenosine signaling, with their efficacy partly dependent on the presence of endogenous adenosine. Despite reported differences in their effects upon adenosine reuptake, both prasugrel and ticagrelor show similar synergistic effects on platelet inhibition in the presence of adenosine or NECA.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Article Hematology

Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity

Abhishek Joshi, Lukas E. Schmidt, Sean A. Burnap, Ruifang Lu, Melissa V. Chan, Paul C. Armstrong, Ferheen Baig, Clemens Gutmann, Peter Willeit, Peter Santer, Temo Barwari, Konstantinos Theofilatos, Stefan Kiechl, Johann Willeit, Timothy D. Warner, Anthony Mathur, Manuel Mayr

Summary: This study found that the proteome of platelets is altered during acute myocardial infarction (MI), and the elevated levels of S100A8 and S100A9 proteins are associated with neutrophil abundance. The study also demonstrated the transfer of proteins between platelets and neutrophils, and the negative correlation between plasma S100A8/A9 and platelet reactivity.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Serotonin-Affecting Antidepressant Use in Relation to Platelet Reactivity

Joseph Grech, Melissa Victoria Chan, Chinedu Ochin, Amber Lachapelle, Florian Thibord, Zoe Schneider, Bongani Brian Nkambule, Paul Charles John Armstrong, Catherine Wallace de Melendez, Katherine L. Tucker, Mahdi Garelnabi, Timothy David Warner, Ming-Huei Chen, Andrew Danner Johnson

Summary: Depression is associated with cardiovascular disease, and platelet reactivity is related to the use of antidepressants, especially those affecting serotonin.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Hematology

Temporal in vivo platelet labeling in mice reveals age-dependent receptor expression and conservation of specific mRNAs

Paul C. Armstrong, Harriet E. Allan, Nicholas S. Kirkby, Clemens Gutmann, Abhishek Joshi, Marilena Crescente, Jane A. Mitchell, Manuel Mayr, Timothy D. Warner

Summary: This study developed a method to label platelet age and found that young platelets exhibit different functional and molecular characteristics compared to older platelets, with increased responsiveness and contribution to thrombus formation. The decrease in thrombotic function with age is accompanied by changes in surface protein expression.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Cell Biology

What can we learn from senescent platelets, their transcriptomes and proteomes?

Harriet E. Allan, Ami Vadgama, Paul C. Armstrong, Timothy D. Warner

Summary: Research on the natural aging process of platelets has attracted much attention in recent years. Previous studies have shown an association between the proportion of newly formed platelets in the circulation and the risk of thrombosis. However, these observations were mainly demonstrated in patient groups with underlying systemic changes. Recent technological advances have allowed in-depth analysis of differently aged platelets from healthy individuals, revealing extensive changes in the transcriptome and proteome of aged platelets. These changes result in deteriorated platelet function, impairing their ability to participate in hemostatic responses.

PLATELETS (2023)

添加到收藏夹

Article Cell Biology

Trends among platelet function, arterial calcium, and vascular function measures

Jason Cunha, Melissa V. Chan, Bongani B. Nkambule, Florian Thibord, Amber Lachapelle, Robin E. Pashek, Ramachandran S. Vasan, Jian Rong, Emelia J. Benjamin, Naomi M. Hamburg, Ming-Huei Chen, Gary F. Mitchell, Andrew D. Johnson

Summary: Arterial tonometry and vascular calcification measures are valuable in assessing cardiovascular disease (CVD) risk. This study examined the relationship between arterial tonometry, platelet function, arterial calcium, and aortic diameter. The results suggest that higher arterial calcium may be associated with increased platelet reactivity, while larger aortic diameter may be linked to lower platelet reactivity. These findings indicate the potential interplay between subclinical atherosclerosis, platelet activation, and vascular structure.

PLATELETS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.